Hemastatx, a spin-off from KU Leuven, has emerged from stealth with its first therapeutic program, HMX-001.
We’re pleased to share that Kevin Hollevoet, PhD, our CEO and co-founder, will attend BioEquity Europe 2025, taking place May 12–14 in Bruges, Belgium.
BioEquity Europe is the leading event for biotech investors and strategic partners, bringing together high-potential companies and the life sciences investment community to shape the future of healthcare innovation.
Hemastatx’s lead program is HMX-001, a first-in-class antibody therapy addressing bleeding episodes in patients with von Willebrand factor (VWF)- related disorders, a space with significant unmet need and market opportunity.
As we work towards upcoming inflection points, we look forward to reconnecting with current partners and engaging with investors, pharma, and other stakeholders.
Interested in connecting with Dr. Hollevoet in Bruges? Please reach out via the BioEquity partnering platform
Published on
May 25, 2025
Share this
Other news & updates
June 21, 2025
Hemastatx at ISTH 2025 – Meet our founders in Washington D.C.
We are excited to announce that our co-founders Prof. Dr. Karen Vanhoorelbeke and Dr. Shannen Deconinck will be representing Hemastatx at the ISTH 2025 Congress.
Organized by the International Society on Thrombosis and Haemostasis, the ISTH Congress is the premier annual event for experts in thrombosis and hemostasis. This year's congress takes place in Washington, D.C., from June 21-25, 2025, and will feature groundbreaking research and networking opportunities.
Dr. Deconinck, Preclinical R&D Lead at Hemastatx, will be delivering an oral communication titled "Therapeutic Efficacy of a Novel Anti-ADAMTS13 Antibody to Treat Acquired von Willebrand Syndrome”. The study was led by KU Leuven Kulak’s Laboratory for Thrombosis Research. Results highlight the potential of Hemastatx’s lead program, HMX-001, to prevent the loss of high-molecular-weight von Willebrand factor multimers and reduce bleeding complications in left ventricular assist device patients.
Join us at the congress to learn more about this promising research and its impact on the treatment of acquired von Willebrand syndrome.